Nyxoah to Participate in the Piper Sandler 37th Annual Healthcare Conference
Rhea-AI Summary
Nyxoah (Nasdaq: NYXH) announced its management team will participate in a fireside chat at the Piper Sandler 37th Annual Healthcare Conference on Thursday, Dec 4, 2025.
The session is scheduled for 1:30 p.m. ET and will be available via a live audio webcast on the company investor relations site at investors.nyxoah.com. The presentation will cover recent corporate developments and provide management commentary to investors and analysts.
Positive
- None.
Negative
- None.
News Market Reaction – NYXH
On the day this news was published, NYXH gained 2.78%, reflecting a moderate positive market reaction. This price movement added approximately $5M to the company's valuation, bringing the market cap to $201M at that time. Trading volume was very high at 3.4x the daily average, suggesting strong buying interest.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
Peers in Medical Instruments & Supplies showed mixed moves, from -2.05% (AVR) and -1.01% (KRMD) to gains of 1.98% (OSUR) and 6.98% (STSS), suggesting NYXH’s modest 0.82% rise was stock-specific rather than a broad sector trend.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Dec 02 | Voting rights update | Neutral | -0.7% | Transparency notifications detailing changes in major shareholder voting rights. |
| Nov 27 | Conference participation | Neutral | +2.8% | Announcement of management fireside chat at Piper Sandler healthcare conference. |
| Nov 20 | Capital structure data | Neutral | +1.5% | Publication of updated share capital, voting rights, and subscription rights figures. |
| Nov 13 | Financing commitments | Positive | -9.8% | Up to U.S. $77M in mixed financing to fund Genio commercialization and R&D. |
| Nov 13 | Q3 2025 earnings | Neutral | -9.8% | Q3 results with revenue growth, FDA-approved launch, and significant operating loss. |
Recent news—governance disclosures, financing, and conference participation—has mostly seen price reactions aligned with the neutral or positive tone, with a notable divergence on the large financing announcement.
Over the last month, Nyxoah issued several governance and financing updates alongside operational progress. On Nov 13, 2025, Q3 results showed revenue of €2.0M and an operating loss of €24.4M, while the same day it announced up to U.S. $77M in financing to support Genio commercialization. Subsequent disclosures on voting rights and capital structure, plus participation in the Piper Sandler conference on Dec 4, 2025, framed a phase of capital raising and investor outreach into which this latest conference participation fits.
Market Pulse Summary
This announcement highlighted Nyxoah’s participation in the Piper Sandler healthcare conference, providing a forum for management to discuss recent developments and strategy. Against a backdrop of substantial recent financing and detailed governance disclosures, the event underscored continued investor engagement efforts. With shares trading below the 200-day MA of 6.74 and significantly under the 52-week high of 11.87, investors may focus on updates around U.S. Genio commercialization, capital deployment, and progress since the latest quarterly results.
Key Terms
obstructive sleep apnea medical
neuromodulation medical
AI-generated analysis. Not financial advice.
Nyxoah to Participate in the Piper Sandler 37th Annual Healthcare Conference
Mont-Saint-Guibert, Belgium – 27 November, 2025, 10:05pm CET / 4:05pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company that develops breakthrough treatment alternatives for Obstructive Sleep Apnea (OSA) through neuromodulation, today announced that the management team will participate in a fireside chat at the Piper Sandler 37th Annual Healthcare Conference on Thursday, Dec. 4, 2025. The fireside chat is scheduled at 1:30 p.m. (ET) the same day via webcast.
A live audio webcast of the presentation will be available online at the investor relations page of the Company’s website at investors.nyxoah.com.
About Nyxoah
Nyxoah is a medical technology company focused on the development and commercialization of innovative solutions to treat OSA. Nyxoah’s lead solution is the Genio system, a patient-centered, leadless and battery-free hypoglossal neurostimulation therapy for OSA, the world’s most common sleep disordered breathing condition that is associated with increased mortality risk and cardiovascular comorbidities. Nyxoah is driven by the vision that OSA patients should enjoy restful nights and feel enabled to live their life to its fullest.
Following the successful completion of the BLAST OSA study, the Genio system received its European CE Mark in 2019. Nyxoah completed two successful IPOs: on Euronext Brussels in September 2020 and NASDAQ in July 2021. Following the positive outcomes of the BETTER SLEEP study, Nyxoah received CE mark approval for the expansion of its therapeutic indications to Complete Concentric Collapse (CCC) patients, currently contraindicated in competitors’ therapy. Additionally, the Company announced positive outcomes from the DREAM IDE pivotal study and receipt of approval from the FDA for a subset of adult patients with moderate to severe OSA with an AHI of greater than or equal to 15 and less than or equal to 65.
For more information, please visit http://www.nyxoah.com/.
Caution – CE marked since 2019. FDA approved in August 2025 as prescription-only device.
Contact:
Nyxoah
John Landry
Chief Financial Officer
IR@nyxoah.com
Rémi Renard
Chief Investor Relations & Corporate Communication Officer
IR@nyxoah.com
Attachment
FAQ
When will Nyxoah (NYXH) present at the Piper Sandler 37th Annual Healthcare Conference?
How can investors watch Nyxoah's (NYXH) fireside chat on Dec 4, 2025?
What topics will Nyxoah (NYXH) management cover at the Piper Sandler conference?
Is Nyxoah's (NYXH) Piper Sandler presentation available after the live webcast?
What time is the Nyxoah (NYXH) webcast for investors in Europe on Dec 4, 2025?
Who is presenting for Nyxoah (NYXH) at the Piper Sandler 2025 conference?
